Powered by
-
GILD Stock Chart
Historical GILD Prices
Gilead Sciences Stock Analysis
Rating: Hold
Total Grade: C
Analysis Breakdown
| GILD Stock Grade: | C |
| Fundamental Grade: | B |
| Quantitative Grade: | D |
| GILD Earnings | |
| Earnings Growth: | D |
| Earnings Momentum: | B |
| Earnings Surprises: | B |
| Analyst Earnings Revisions: | A |
| GILD Financial Information | |
| Sales Growth: | F |
| Operating Margin Growth: | C |
| Cash Flow: | B |
| Return on Equity: | A |
Gilead Sciences Stock: Weekly View
| This Week: | C |
|---|---|
| Last Week: | C |
| Two Weeks Ago: | C |
GILD Stock predictions, Articles, and Gilead Sciences News
- From InvestorPlace
- From the Web
-
Weak Industry Group Rank Hampers Gilead Sciences (GILD) Rating - October 23, 2017
Currently, Gilead Sciences Inc (NASDAQ:GILD) has a Hold using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methods. GILD has maintained this ranking for the last month. Continue…
-
Gilead Sciences (GILD) Sales Growth Hampers Rating - October 16, 2017
Portfolio Grader currently ranks Gilead Sciences Inc (NASDAQ:GILD) a Hold. The methods for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. GILD has maintained this ranking for the last month. Continue…
-
It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock - October 13, 2017
Gilead has been sliding, but HCV market consolidation and potential exponential growth in the CAR-T market imply upside for GILD stock. Continue…
-
Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy - October 13, 2017
Gilead Sciences’ Kite pharma deal is a good move while the underlying business in Hepatitis and HIV grows in 2018. Continue…
-
Gilead Sciences (GILD) Raised to Hold from a Sell - October 9, 2017
Currently, Gilead Sciences Inc (NASDAQ:GILD) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. GILD has been upgraded from a Sell to a Hold in the last week. Continue…
-
4 Biotech Stocks (and 1 ETF) to Buy As They Bolt Higher - October 2, 2017
These biotech stocks are making a comeback amid several positive catalysts for the sector and markets as a whole. Continue…
-
How Will Trump’s Proposed Tax Reform Impact Drug Companies? - September 29, 2017
Donald Trump has proposed new tax reforms for individuals and corporates. Let’s see how the reforms, if passed, will impact pharma companies. Continue…
-
Gilead Sciences, Inc. (GILD) Stock Got Its Mojo Back - September 29, 2017
For a while GILD stock was a hideous knife to catch. But now that it reestablished its bottom, I can safely make money in Gilead. Continue…
-
3 Sector-Specific Trades to Start the Week Off Right - September 25, 2017
These three diversified plays for options trading -- GES, NVDA and GILD -- come from three different sectors and look golden. Continue…
-
Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade - September 21, 2017
JUNO stock has a lot going for it, but a bullish position looks a good deal better when fully-immunized with an options hedge. Continue…
